Charity D. Scripture
13 Papers
26 Citations
Charity D. Scripture is an academic researcher. The author has contributed to research in topics: Paclitaxel & Medicine. The author has an hindex of 11, co-authored 13 publications.
Chat about Author
Papers
Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)
Alex Sparreboom,Charity D. Scripture,Vuong Trieu,Paul J. Williams,Tapas De,Andrew Yang,Bridget Beals,William D. Figg,Michael J. Hawkins,Neil Desai +9 more
TL;DR: The volume of distribution at steady state and clearance for paclitaxel formulated as Cremophor-free nanoparticle ABI-007 were significantly greater than those for paclitexel formulated with Cremophileor (Taxol) in rats, consistent with the absence of pac litaxel-sequestering Cremphor micelles after administration of A BI-007.
504
Drug interactions in cancer therapy.
TL;DR: The types of drug interaction that occur in oncology, the mechanisms that underlie these interactions and examples are outlined and select examples are described.
352
Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives.
TL;DR: This review focuses on recent advances in the etiology of paclitaxel-mediated peripheral neurotoxicity, and discusses current and ongoing strategies for amelioration of this side effect.
305
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel
Erin R. Gardner,William L. Dahut,Charity D. Scripture,Jacquin Jones,Jeanny B. Aragon-Ching,Neil Desai,Michael J. Hawkins,Alex Sparreboom,William D. Figg +8 more
TL;DR: Because systemic exposure to unbound paclitaxel is likely a driving force behind tumoral uptake, these findings explain, at least in part, previous observations that the administration of nab-paclitaxe is associated with augmented antitumor efficacy compared with solvent-based pac litaxel.
229
A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer
William L. Dahut,Charity D. Scripture,Edwin M. Posadas,Lokesh Jain,James L. Gulley,Philip M. Arlen,John Wright,Yunkai Yu,Liang Cao,Seth M. Steinberg,Jeanny B. Aragon-Ching,Jürgen Venitz,Elizabeth C. Jones,Clara C. Chen,William D. Figg +14 more
TL;DR: Sorafenib is relatively well tolerated in AIPC with two patients showing evidence of improved bony metastatic lesions and in vitro studies suggested that PSA is not a good marker of sorafenIB activity.
183